journal article·2016-11-16

Enhancing activity of artesunate against breast cancer cells via induced-apoptosis pathway by loading into lipid carriers

Tuan Hiep Tran, Anh Ngoc Nguyen, Jong Oh Kim, Chul Soon Yong, Chien Ngoc Nguyen

Publisher page

Abstract

Artesunate-loaded nanostructured lipid carriers (ART-NLCs) were prepared by hot homogenization followed by ultrasonication technique. The optimized ART-NLC demonstrated a particle size of 117.5 ± 6.1 nm, with good stability regarding zeta-potential of -19.47 ± 0.9 mV and drug entrapment efficiency of 92.93 ± 1.47%. ART-NLC showed good cellular uptake in breast cancer cells, which was confirmed by confocal laser scanning microscopy (CLSM) and flow cytometry analysis. The significantly higher in vitro cytotoxicity of ART-NLCs against human breast cancer MCF-7, MDA-MB-231 cells as compared with the free ART was recorded. Hoechst 33342 staining indicated that ART-NLC induced higher apoptosis rates in MCF-7 as well as MDA-MB-231cells than free ART.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Lipid Membrane Structure and Behavior · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (27)

Show source-provided references
1. 10.3109/03639045.2012.65881210.3109/03639045.2012.658812 ↗
2. 10.1039/C4TB01442A10.1039/C4TB01442A ↗
3. 10.1016/j.ijpharm.2013.08.06910.1016/j.ijpharm.2013.08.069 ↗
4. 10.1016/j.ejpb.2014.02.00510.1016/j.ejpb.2014.02.005 ↗
5. 10.1016/S0731-7085(02)00678-710.1016/S0731-7085(02)00678-7 ↗
6. 10.1074/jbc.M110.21004710.1074/jbc.M110.210047 ↗
7. 10.1016/j.ijbiomac.2012.01.02410.1016/j.ijbiomac.2012.01.024 ↗
8. 10.3109/10717544.2014.97538210.3109/10717544.2014.975382 ↗
9. 10.1016/j.ijpharm.2012.03.03210.1016/j.ijpharm.2012.03.032 ↗
10. 10.1016/S0169-409X(01)00105-310.1016/S0169-409X(01)00105-3 ↗
11. 10.1016/j.colsurfb.2013.11.03910.1016/j.colsurfb.2013.11.039 ↗
12. 10.1016/j.colsurfb.2013.03.03710.1016/j.colsurfb.2013.03.037 ↗
13. 10.1016/S0169-409X(02)00118-710.1016/S0169-409X(02)00118-7 ↗
14. 10.1016/j.ejps.2012.10.02510.1016/j.ejps.2012.10.025 ↗
15. 10.1007/s12272-014-0424-310.1007/s12272-014-0424-3 ↗
16. 10.1016/j.ejpb.2011.03.02210.1016/j.ejpb.2011.03.022 ↗
17. 10.1016/j.actbio.2014.08.02110.1016/j.actbio.2014.08.021 ↗
18. 10.1016/j.carbpol.2013.11.00910.1016/j.carbpol.2013.11.009 ↗
19. 10.1021/mp400640810.1021/mp4006408 ↗
20. 10.1016/j.ijpharm.2007.03.02210.1016/j.ijpharm.2007.03.022 ↗
21. 10.1016/j.addr.2010.03.01110.1016/j.addr.2010.03.011 ↗
22. 10.1016/j.carbpol.2014.08.02610.1016/j.carbpol.2014.08.026 ↗
23. 10.1208/s12249-014-0175-y10.1208/s12249-014-0175-y ↗
24. 10.1007/s11095-014-1300-z10.1007/s11095-014-1300-z ↗
25. 10.1016/j.molstruc.2014.12.08710.1016/j.molstruc.2014.12.087 ↗
26. 10.1631/jzus.B100037310.1631/jzus.B1000373 ↗
27. 10.1016/j.ijpharm.2008.06.00210.1016/j.ijpharm.2008.06.002 ↗